Monday, BioNTech SE (NASDAQ:BNTX) reported a first-quarter EPS loss of 1.31 euros ($1.41 loss), a shift from an income of 2.05 euros, missing the consensus loss of 97 cents. The COVID-19 vaccine maker reported sales of 187.6 million euros (roughly $202 million), down from 1.3 billion euros reported a year ago, missing the consensus of 427.5 million euros. The European biotech firm posted a quarterly net loss of 315 million euros, compared with a profit of 502 million a year earlier. “We expect to recognize approximately 90% of our full year revenues in the ...